2076975 2077203
최종편집 2020-07-14 14:07 (화)
ARB antihypertensive drugs grow slowly, but Diovan still guarantees its strength
상태바
ARB antihypertensive drugs grow slowly, but Diovan still guarantees its strength
  • Hyeokgi Lee, Newsmp
  • 승인 2020.06.21 13:30
  • 댓글 0
이 기사를 공유합니다

Double-digit growth alone among the off-patent single ARB drugs in the first quarter
Edalbi exceeds $2 billion in sales… Kanarb is in the lead
Popular complex ARB+CCB drugs stay at 5% of growth rate

In the first quarter, the growth of the popular ARB antihypertensive agents showed a significant slowdown.

Even in the aftermath of COVID-19, most of the growth rate remained around 5%.

Nevertheless, in 2018, Diovan (Novartis), which has rebounded since NDMA, classified as a carcinogen, was detected in some Valsartan generics, continued to develop itself.

According to IQVIA, Diovan’s sales surpassed $7 billion in the first quarter, with an increase in 14.6% compared to last year.

The growth seemed stagnant during the third and fourth quarters by remaining its sales about $6.9 billion, but it is on the upturn with a $7 billion range.

Although Diovan is narrowing the gap by remarkably expanding its sales, there has been no change in Kanarb’s (Boryung Pharm.) market dominance. 

Kanarb, which exceeded $9 billion in the second quarter of last year, raised its sales to $9.4 billion in the first quarter. The growth was also the second highest among off-patent ARB original drugs after Diovan.

Atacand (Astra Zeneca) and Cozaar (MSD) both achieved $6 billion in sales with a 5.5% growth rate. 

Atacand, which consistently had $6 billion sales until the third quarter of last year, retreated to $5.9 billion in the fourth quarter, but immediately returned to $6 billion.

While all four leading group drugs reserved more than 5% of growth rate, the rest of the ARB original medicines had a low growth rate of less than 5%. 

Micardis (Boehringer Ingelheim) had the highest growth rate (4%), and Olmetec (DaeWoong Pharm) and Aprovel (Sanofi) both recorded 2.4% growth, however, Teveten (Handok) grew 14.3% backward resulting quarterly earnings under $500 million.

Edalbi (Takeda), which entered the market latest and still maintains patent with Kanarb, made $2 billion after its launch with a growth rate of over 30%.

▲ The growth of the popular ARB antihypertensive agents showed a significant slowdown in the first quarter.
▲ The growth of the popular ARB antihypertensive agents showed a significant slowdown in the first quarter.

The first generation of complex ARB+CCB drugs also appeared to be poor growth. Nonetheless, Twynsta (Boehringer Ingelheim) has entered the $20 billion mark despite its 5.8% growth rate.

Exforge (Novartis), which has grown considerably after the detection of Valsartan’s generic NDMA, showed only 5.7% growth in the first quarter, unlike Diovan, which recorded a double-digit growth rate for the same reason. 

However, quarterly earnings, which remained at $17 billion marks throughout the fourth quarter of last year, reached $18 billion marks with $18.4 billion. 

Amosartan (Hanmi Pharm.) also achieved sales of $12 billion for the second quarter in a row with a 5.9% growth rate, but Sevikar (Daiichi Sankyo) and Telminuvo (Chong Kun Dang Pharm.) fell behind the leading group with a growth rate of 3.7% and 1.2%.

Meanwhile, in the ARB+CCB+Diuretics three-drug combination market, sales of Sevikar HCT (Daiichi Sankyo), which kept growing backward after patent expiration, increased by 0.5%, and it was out of the degrowth trend with low growth. 

Amosartan Plus (Hanmi Pharm.) rose to $4 billion with a 30% growth rate, while Twotops Plus (Ildong Pharm.) also continued to grow. 
 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.